Skip to main content
Journal cover image

Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing.

Publication ,  Journal Article
Menkovic, I; Makhijani, N; Francescatto, L; Pendyal, S; Stanley, C; Young, SP; Koeberl, DD; Niyazov, D; Stiles, AR
Published in: Mol Genet Metab Rep
December 2025

3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency is a rare autosomal recessive metabolic disease caused by variants in the HMGCL gene leading to an impairment in leucine catabolism and ketone synthesis. In the United States, HMG-CoA lyase deficiency is listed on the recommended uniform screening panel as a core condition for newborn screening. A positive newborn screen will typically show an elevation of C5-hydroxylated species on the acylcarnitine profile using a dried-blood spot collected between 24 and 48 h of life. Initial follow-up testing generally includes a plasma acylcarnitine profile and a urine organic acid profile. Clinically, this metabolic alteration can lead to severe metabolic decompensation, presenting as hypoketotic hypoglycemia and, when left untreated, potential long-term neurological impairments. This report highlights the case of a 38-day-old male with an initial abnormal newborn screen. Follow-up testing showed moderate elevations of C5-hydroxylated and C6-dicarboxylated species on the plasma acylcarnitine profile and marked elevations of 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, 3-methylglutaric and 3-hydroxyisovaleric acid detected by urine organic acid analysis. These findings were consistent with a biochemical diagnosis of HMG-CoA lyase deficiency. Confirmatory molecular testing included targeted HMGCL sequencing including deletion/duplication analysis; the results of which were negative. Genome sequencing was then requested which identified a deep intronic complex variant of unknown significance within intron 1 of HGMCL. RNA sequencing studies were sent as follow-up which revealed that the level of expression of the HMGCL gene was negligible in comparison with tissue-matched controls, thus confirming the biochemical diagnosis of HMG-CoA lyase deficiency.

Duke Scholars

Published In

Mol Genet Metab Rep

DOI

ISSN

2214-4269

Publication Date

December 2025

Volume

45

Start / End Page

101278

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 0604 Genetics
  • 0601 Biochemistry and Cell Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Menkovic, I., Makhijani, N., Francescatto, L., Pendyal, S., Stanley, C., Young, S. P., … Stiles, A. R. (2025). Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing. Mol Genet Metab Rep, 45, 101278. https://doi.org/10.1016/j.ymgmr.2025.101278
Menkovic, Iskren, Neelam Makhijani, Ludmila Francescatto, Surekha Pendyal, Christine Stanley, Sarah P. Young, Dwight D. Koeberl, Dmitriy Niyazov, and Ashlee R. Stiles. “Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing.Mol Genet Metab Rep 45 (December 2025): 101278. https://doi.org/10.1016/j.ymgmr.2025.101278.
Menkovic I, Makhijani N, Francescatto L, Pendyal S, Stanley C, Young SP, et al. Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing. Mol Genet Metab Rep. 2025 Dec;45:101278.
Menkovic, Iskren, et al. “Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing.Mol Genet Metab Rep, vol. 45, Dec. 2025, p. 101278. Pubmed, doi:10.1016/j.ymgmr.2025.101278.
Menkovic I, Makhijani N, Francescatto L, Pendyal S, Stanley C, Young SP, Koeberl DD, Niyazov D, Stiles AR. Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing. Mol Genet Metab Rep. 2025 Dec;45:101278.
Journal cover image

Published In

Mol Genet Metab Rep

DOI

ISSN

2214-4269

Publication Date

December 2025

Volume

45

Start / End Page

101278

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 0604 Genetics
  • 0601 Biochemistry and Cell Biology